Get the Stockscreener App
17.45
3.67%
0.6488
Greenwich Lifesciences Inc stock is traded at $17.45, with a volume of 66,177.
It is up +3.67% in the last 24 hours and up +6.71% over the past month.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
See More
Previous Close:
$16.80
Open:
$16.8
24h Volume:
66,177
Relative Volume:
0.43
Market Cap:
$256.06M
Revenue:
-
Net Income/Loss:
$-21.76M
P/E Ratio:
-11.27
EPS:
-1.5479
Net Cash Flow:
$-12.78M
1W Performance:
+12.36%
1M Performance:
+6.71%
6M Performance:
-31.00%
1Y Performance:
+43.10%
1-Day Range:
$16.55
$17.47
1-Week Range:
$14.80
$17.74
52-Week Range:
$7.78
$34.10
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
17.45 | 246.59M | 0 | -21.76M | -12.78M | -1.5479 |
VRTX
Vertex Pharmaceuticals Inc
|
515.89 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.79 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.63 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.22 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.16 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Noble Capital Markets | Outperform |
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
What’s Driving GLSI Stock Today? - Stocktwits
Greenwich Lifesciences Stock Price Forecast. Should You Buy GLSI? - StockInvest.us
Greenwich Lifesciences Inc (NASDAQ: GLSI) Share Price, GLSI Stock News, GLSI Share Price & Updates - Kalkine
Why Did GLSI Stock Rise Pre-Market Today? - Stocktwits
Greenwich Lifesciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Greenwich LifeSciences (NASDAQ:GLSI) Posts Quarterly Earnings Results - MarketBeat
Greenwich LifeSciences 2Q 2026: Revenue $0 Net loss $(3.95M), EPS $(0.27) — 10-Q Summary - TradingView
Greenwich LifeSciences, Inc. (GLSI) stock price, news, quote and history - Yahoo Finance Singapore
Greenwich Lifesciences Inc expected to post a loss of 33 cents a shareEarnings Preview - TradingView
Responsive Playbooks and the GLSI Inflection - Stock Traders Daily
Greenwich LifeSciences Extends Insider and Pre-IPO Share Lock-Up to January 31, 2027 - Quiver Quantitative
Greenwich LifeSciences Directors, Officers Face 100% Lock-Up to 2027 - Stock Titan
Greenwich LifeSciences (GLSI) Expected to Post Earnings on Thursday - MarketBeat
GLSI|Greenwich Lifesciences Inc|Price:13.400|Chg%:-0.100 - TradingKey
Understanding the Setup: (GLSI) and Scalable Risk - Stock Traders Daily
Form 4 Greenwich Lifesciences Inc For: 30 July By Investing.com - Investing.com Nigeria
Greenwich LifeSciences CEO Snehal Patel buys $29,555 in stock By Investing.com - Investing.com Nigeria
Greenwich LifeSciences CEO Snehal Patel buys $29,555 in stock - Investing.com
Greenwich LifeSciences CEO Snehal Patel buys $20,430 in shares By Investing.com - Investing.com UK
Form 4 Greenwich Lifesciences Inc For: 29 July By Investing.com - Investing.com Canada
Greenwich LifeSciences, Inc. (GLSI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Purchases 2,500 Shares - MarketBeat
Greenwich Lifesciences Inc (GLSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GLSI|Greenwich Lifesciences Inc|Price:13.470|Chg%:+0.490 - TradingKey
Form 4 Greenwich Lifesciences Inc For: 27 July By Investing.com - Investing.com Nigeria
Greenwich LifeSciences CEO buys $47,018 in company stock By Investing.com - Investing.com Canada
Greenwich LifeSciences CEO buys $47,018 in company stock - Investing.com
Greenwich LifeSciences (NASDAQ: GLSI) CEO adds 3,600 shares in open-market buys - Stock Titan
Greenwich LifeSciences, Inc. Revenue Breakdown – NASDAQ:GLSI - TradingView
Greenwich Lifesciences Inc (GLSI) Cash Flow - TradingKey
TradingKey - TradingKey
Greenwich Lifesciences Inc (GLSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Greenwich Lifesciences Inc (GLSI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Greenwich Lifesciences Inc (GLSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Greenwich Lifesciences Inc (GLSI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Greenwich Lifesciences Inc (GLSI) Institutional Confidence - TradingKey
Greenwich Lifesciences Inc (GLSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
HC Wainwright Issues Optimistic Forecast for GLSI Earnings - MarketBeat
Greenwich LifeSciences adds up to 10 UK trial sites - grafa.com
Greenwich LifeSciences gains UK approval for breast cancer trial By Investing.com - Investing.com South Africa
Greenwich LifeSciences Gets UK Clearance to Expand Breast Cancer Trial - Moomoo
Greenwich LifeSciences gains UK approval for breast cancer trial - Investing.com
Greenwich LifeSciences secures regulatory approval to expand FLAMINGO-01 trial into United Kingdom - Traders Union
Greenwich LifeSciences Announces UK Regulatory Approval to Expand Phase III FLAMINGO-01 Breast Cancer Trial - Quiver Quantitative
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom - The Manila Times
UK approval could add 5-10 sites to Greenwich LifeSciences trial - Stock Titan
Greenwich Lifesciences Announces Approval To Expand FLAMINGO-01 Into The United Kingdom - TradingView
Greenwich LifeSciences: Building Pivotal Trial Momentum, But Still Not Moving The Needle For Me - Seeking Alpha
HC Wainwright Forecasts Strong Price Appreciation for Greenwich LifeSciences (NASDAQ:GLSI) Stock - MarketBeat
Greenwich LifeSciences expands Phase III breast cancer trial - grafa.com
Why is Greenwich LifeSciences stock rallying today? By Investing.com - Investing.com Canada
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Greenwich Lifesciences Inc Stock (GLSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Jul 29 '26 |
Buy |
13.10 |
700 |
9,170 |
5,611,402 |
| Patel Snehal | CEO and CFO |
Jul 27 '26 |
Buy |
13.62 |
1,500 |
20,430 |
5,609,202 |
| Patel Snehal | CEO and CFO |
Jul 23 '26 |
Buy |
13.14 |
2,500 |
32,850 |
5,606,602 |
| Patel Snehal | CEO and CFO |
Jul 24 '26 |
Buy |
12.88 |
1,100 |
14,168 |
5,607,702 |
| Patel Snehal | CEO and CFO |
Jan 13 '26 |
Buy |
29.83 |
1,800 |
53,694 |
5,604,102 |
| Patel Snehal | CEO and CFO |
Jan 12 '26 |
Buy |
27.54 |
2,900 |
79,866 |
5,602,302 |
| Patel Snehal | CEO and CFO |
Dec 31 '25 |
Buy |
21.36 |
4,300 |
91,848 |
5,599,402 |
| Patel Snehal | CEO and CFO |
Dec 30 '25 |
Buy |
21.73 |
2,900 |
63,017 |
5,595,102 |
| Patel Snehal | CEO and CFO |
Dec 18 '25 |
Buy |
12.62 |
4,100 |
51,742 |
5,592,202 |
| Patel Snehal | CEO and CFO |
Nov 25 '25 |
Buy |
8.37 |
4,600 |
38,502 |
5,588,102 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):